Редактирование: NR1I2

Nuclear receptor subfamily 1 group I member 2 (Orphan nuclear receptor PAR1) (Orphan nuclear receptor PXR) (Pregnane X receptor) (Steroid and xenobiotic receptor) (SXR) [PXR]

==Publications==

{{medline-entry
|title=A drug transporter for all ages? [[ABCB1]] and the developmental pharmacogenetics of cyclosporine.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/18518855
|abstract=Evaluation of: Fanta S, Niemi M, Jönsson S et al.: Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of [[ABCB1]]polymorphisms. Pharmacogenet. Genomics 18(2), 77-90 (2008). The clinical use of the immunosuppressive agent cyclosporine is complicated by its toxicity, narrow therapeutic window and highly variable pharmacokinetics between individuals. In adults, genetic polymorphisms in the genes encoding the cyclosporine-metabolizing enzymes [[CYP3A4]] and [[CYP3A5]], as well as the [[ABCB1]] gene, which encodes the efflux-pump P-glycoprotein, seem to have a limited effect, if any, on cyclosporine pharmacokinetics. However, the authors have now reported for the first time an association between cyclosporine oral bioavailability and the [[ABCB1]] c.1236C>T and c.2677G>T polymorphisms, as well as the related haplotype c.1199G-c.1236C-c.2677G-c.3435C, in children with end-stage renal disease older than 8 years of age. Carriers of the variant alleles had a cyclosporine oral bioavailability that was around 1.5-times higher compared with noncarriers. This association was not observed in children younger than 8 years of age. In addition, no relation between cyclosporine disposition and genetic variation in the [[CYP3A4]], [[CYP3A5]], [[ABCC2]], [[SLCO1B1]] and [[NR1I2]] genes was observed. These data suggest that the effect of [[ABCB1]] polymorphisms on cyclosporine pharmacokinetics is related to age, and thus developmental stage. Although further study is necessary to establish the predictive value of [[ABCB1]] genotyping for individualization of cyclosporine therapy in children older than 8 years, an important step towards further personalized immunosuppressive drug therapy has been made.
|mesh-terms=* ATP Binding Cassette Transporter, Subfamily B
* ATP Binding Cassette Transporter, Subfamily B, Member 1
* Adult
* Aging
* Child
* Cyclosporine
* Humans
* Immunosuppressive Agents
* Inactivation, Metabolic
* Kidney Transplantation
* Pharmacogenetics
* Polymorphism, Single Nucleotide

|full-text-url=https://sci-hub.do/10.2217/14622416.9.6.783
}}